THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY


*fictional patients used for illustrative purposes

Brintellix (vortioxetine) is indicated for the treatment
of major depressive episodes in adults.1
Adverse events should be reported.

Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Lundbeck Limited, Medical Information, on: 01908 638972 or Email: SafetyLuUnitedKingdom@lundbeck.com

References
  • Lundbeck. Brintellix. Summary of Product Characteristics GB and NI.
  • Chokka P et al. CNS Spectrums. 2019 Dec;24(6):616-27.
  • Cao B et al. Frontiers in psychiatry. 2019 Jan 31;10:17.
  • Baune BT et al. Int J Neuropsychopharm. 2018 Feb;21(2):97-107.
  • Fagiolini A et al. J Affect Disord. 2021 Mar 15;283:472-9.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition, Text Revision (DSM-5-TR). 2022. American Psychiatric Association Publishing. https://doi.org/10.1176/appi.books.9780890425787. [Last accessed September 2023].
  • McClintock SM et al. J Clin Psychopharmacol 2011;31:180-186.
UK-BRIN-1277 | September 2023

This is a Lundbeck Limited developed and funded website intended for UK healthcare professionals only. This website contains promotional materials.

Please select the link below that is most relevant to you:

UK-BRIN-1539 | February 2024